List of Spinraza drug patents
Spinraza is owned by Biogen Idec.
Spinraza contains Nusinersen Sodium.
Spinraza has a total of 9 drug patents out of which 0 drug patents have expired.
Spinraza was authorised for market use on 23 December, 2016.
Spinraza is available in solution;intrathecal dosage forms.
Spinraza can be used as treatment of spinal muscular atrophy; treatment of spinal muscular atrophy by inhibiting an smn2 pre-mrna intronic splicing silencer site; treatment of spinal muscular atrophy by increasing exon-7 inclusion in smn2 mrna, treatment of infantile-onset spinal muscular atrophy, treatment of spinal muscular atrophy by increasing exon-7 inclusion in smn2 mrna; treatment of type iii spinal muscular atrophy; treatment of type ii spinal muscular atrophy; treatment of spinal muscular atrophy, treatment of spinal muscular atrophy by inhibiting an smn2 pre-mrna intronic splicing silencer site; treatment of spinal muscular atrophy by increasing exon-7 inclusion in smn2 mrna; treatment of spinal muscular atrophy, treatment of spinal muscular atrophy, treatment of type iii spinal muscular atrophy; treatment of spinal muscular atrophy; treatment of infantile-onset spinal muscular atrophy; treatment of type ii spinal muscular atrophy; treatment of spinal muscular atrophy by inhibiting an smn2 pre-mrna intronic splicing silencer site; treatment of spinal muscular atrophy by increasing exon-7 inclusion in smn2 mrna.
The generics of Spinraza are possible to be released after 11 September, 2035.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7101993 | BIOGEN IDEC | Oligonucleotides containing 2′-O-modified purines |
Sep, 2023
(3 months from now) | |
| US7838657 | BIOGEN IDEC | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
Jul, 2027
(4 years from now) | |
| US8361977 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing |
May, 2030
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8110560 | BIOGEN IDEC | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
Dec, 2025
(2 years from now) | |
| US10266822 | BIOGEN IDEC | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
Dec, 2025
(2 years from now) | |
| US9717750 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing in a subject |
Jun, 2030
(7 years from now) | |
| US8980853 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing in a subject |
Nov, 2030
(7 years from now) | |
| US9926559 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing in a subject |
Jan, 2034
(10 years from now) | |
| US10436802 | BIOGEN IDEC | Methods for treating spinal muscular atrophy |
Sep, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 23, 2023 |
Drugs and Companies using NUSINERSEN SODIUM ingredient
Market Authorisation Date: 23 December, 2016
Treatment: Treatment of spinal muscular atrophy; Treatment of spinal muscular atrophy by inhibiting an smn2 pre-mrna intronic splicing silencer site; Treatment of spinal muscular atrophy by increasing exon-7 inc...
Dosage: SOLUTION;INTRATHECAL
SPINRAZA family patents
44
United States
11
European Union
7
Korea, Republic of
6
Japan
5
Denmark
5
Spain
5
Portugal
5
Poland
4
Cyprus
4
Slovenia
4
China
4
Hungary
4
Lithuania
3
Hong Kong
3
Mexico
2
Australia
2
Israel
2
Croatia
2
New Zealand
2
Chile
2
Russia
1
Colombia
1
Luxembourg
1
Canada
1
Norway
1
Brazil
1
Turkey
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic